Thyroid Eye Disease

Teprotumumab adherence rates are high in patients with TED

Posted on

Patients with thyroid eye disease (TED) appear to adhere to treatment with teprotumumab in clinical practice like controlled trial findings, according to a study.

In this real-world analysis, 1101 patients who began treatment with teprotumumab before July 2020 were evaluated for the number of infusions and baseline characteristics.

Patients received a mean of 7.7 ± 1.2 infusions. Overall, 90% (n = 995) completed a full course of 8 infusions. Of those that discontinued treatment, 8% (n = 84) did so due to adverse events, 1% (n = 15) due to noncompliance, <1% (n = 5) due to site-of-care challenges or payer restrictions, and <1% (n =6) due to patient or physician concern.

“When considering treatment options, it is critical to balance desired efficacy with the potential for adverse events or other factors that may hinder adherence to treatment,” said Roger A. Dailey, MD, FACS, study investigator and professor of ophthalmology, oculofacial plastic surgery and dermatology, Casey Aesthetic Facial Surgery Center at Oregon Health & Science University’s Casey Eye Institute in a press release. “These results, which show patients are committed to finishing this therapy for thyroid eye disease, should give physicians further confidence in medical management of this devastating condition.”

Douglas RS. Real-World Adherence With Teprotumumab in TED. Presented at: AAO 2021.